Skip to main content
Caplight Logo









SynGenis

SynGenis

Private
BentleyHealthcare & Life Scienceshttps://www.syngenis.com/

Last Round

Growth Equity

Jul 12, 2026

Total Funding Raised

$2.78M

Company Overview

SynGenis is a biotechnology company that specializes in the production and supply of high-quality oligonucleotides for diagnostic and therapeutic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

oligonucleotide synthesiscustom oligonucleotidesmolecular diagnosticsASOantisense oligonucleotidessiRNACRISPR guide RNAbiotech manufacturingGMP manufacturingAI drug discoveryin silico designsequence optimizationcontract manufacturingbiotech supply chainDNA synthesisRNA synthesissynthetic biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SynGenis Comparables

Compare SynGenis with similar companies based on industry and business-model similarity.

SynGenis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synoligo Biotechnologies
83%
Messenger Bio
74%
Danaher
72%

SynGenis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Growth EquityJul 12, 2026
SeedMar 1, 2021

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2026

    Grew 63% QoQ, from 8 to 13 employees.

  • Apr 11, 2026

    Grew 71% QoQ, from 7 to 12 employees.

Recent news

Latest coverage and updates

  • is_developingAug 24, 2026

    SynGenis Pty Ltd is developing artificial intelligence engine.

  • receives_financingAug 24, 2026

    SynGenis Pty Ltd received financing of $363K on Aug 25th '26.

  • invests_into_assetsAug 24, 2026

    SynGenis Pty Ltd will invest into assets: Good Manufacturing Practice (GMP) facility in Australia, Australia and New Zealand, Oceania on Jan 1st '27.

  • receives_financingJul 13, 2026

    SynGenis Pty Ltd received financing of $4M in pre-IPO on Jul 13th '26.

SynGenis Filings

Explore SEC and related filing metadata, where available.

SynGenis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SynGenis's valuation, stock price, and market status.

Is SynGenis a public or private company?

SynGenis is a private company.

What is the current stock price of SynGenis?

SynGenis is a private company with no public stock price. No recent secondary market data is available.

How much is SynGenis worth (valuation)?

Valuation information for SynGenis is not publicly available.

Can I buy SynGenis stock?

SynGenis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SynGenis's last funding round?

SynGenis's most recent funding round was Growth Equity on July 12, 2026.

Who are the main investors in SynGenis?

Investor information for SynGenis is not publicly disclosed.

Will SynGenis IPO soon?

No public IPO plans have been announced for SynGenis.

How can I track SynGenis secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SynGenis's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBentley
Employee Range13
Year Founded2020
Last FundingJul 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?